Nova Mentis Life Science Corp.

As of September 30, 2023, Nova Mentis Life Science Corp. has 29.43M shares outstanding.

These figures are as of September 30, 2023. The price-to-sales ratio is 129.31, and the price-to-book ratio stands at -0.41.

As of September 30, 2023, Nova Mentis Life Science Corp. maintains a current ratio of 0.06, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended September 30, 2023. Return on assets (ROA) is negative at -343.51, reflecting losses generated across the asset base.

Over the twelve months ended September 30, 2023, Nova Mentis Life Science Corp. posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -5,090.78 and net profit margin of -7,352.31 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2023. Free cash flow yield is negative at -12.69: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.75, meaning Nova Mentis Life Science Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Nova Mentis Life Science Corp.'s most recent stock split took place on June 26, 2020 with a 4:1 split ratio.

As of September 30, 2023, Nova Mentis Life Science Corp. has an Altman Z-Score of -1,633.04, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.